First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma

NCT05188859 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Mesothelioma, Malignant
Mesothelioma, Malignant Pleural
Mesothelioma Malignant Advanced

Interventions

DRUG: Sintilimab+Anlotinib+Pemetrexed+Cisplatin

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences